PeptideDB

Schisandrol B

CAS No.: 58546-54-6

1. Schisandrol B (Besigomsin) may exert neuroprotective effects by attenuating the microglia-mediated neuroinflammatory
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Description 1. Schisandrol B (Besigomsin) may exert neuroprotective effects by attenuating the microglia-mediated neuroinflammatory response via inhibiting the TLR4-mediated NF-κB and MAPKs signaling pathways. 2. Schisandrol B has anti-inflammatory property, potentially result from the inhibition of COX-2, iNOS, IL-6, TNF-α and NO through the down-regulation of RIP2 and NF-κB activation. 3. Schisandrol B induces marked protective effects against hepatic and renal injury induced by CCl(4) exposure through differential regulation of the MAPK signal transduction pathway. 4. Schisandrol B significantly inhibits cell proliferation in a dose-dependent manner, due to cell cycle arrest in the G1 phase with the downregulation of cyclin D1 expression and Retinoblastoma (RB) phosphorylation.
Synonyms Gomisin A, TJN-101, Besigomsin, 五味子醇乙, Gamma-Schisandrin, 戈米辛A, Schizandrol B, Wuweizi alcohol-B
molecular weight 416.46
Molecular formula C23H28O7
CAS 58546-54-6
Storage keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility DMSO: 50 mg/mL (120.06 mM)
References 1. Hwang, Dae. Protective effects of gomisin A isolated from Schisandra chinensis against CCl4-induced hepatic and renal injury[J]. International Journal of Molecular Medicine, 2013, 31(4):888---898.